The National Institute of Mental Health Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) project: schizophrenia trial design and protocol development.
about
Perphenazine for schizophreniaAntipsychotic drug treatment for elderly people with late-onset schizophreniaAripiprazole versus placebo for schizophreniaAmphetamines for Attention Deficit Hyperactivity Disorder (ADHD) in adultsClozapine versus other atypical antipsychotics for schizophreniaClozapine versus typical neuroleptic medication for schizophreniaRisperidone versus olanzapine for schizophreniaClozapine versus other atypical antipsychotics for schizophreniaRisperidone versus olanzapine for schizophreniaAripiprazole for schizophreniaAripiprazole for schizophreniaA "SMART" design for building individualized treatment sequencesGenomewide pharmacogenomic study of metabolic side effects to antipsychotic drugsCurrent perspectives in the treatment of resistant schizophreniaSurvey on schizophrenia treatment in Mexico: perception and antipsychotic prescription patternsGenotype-based ancestral background consistently predicts efficacy and side effects across treatments in CATIE and STAR*DGenomewide association for schizophrenia in the CATIE study: results of stage 1Cross-disorder genomewide analysis of schizophrenia, bipolar disorder, and depressionEndophenotypes in Schizophrenia for the Perinatal Period: Criteria for Validation.A Role for Oxytocin in the Etiology and Treatment of Schizophrenia.No association of a set of candidate genes on haloperidol side effects.Comparison of antipsychotic medication effects on reducing violence in people with schizophreniaResults of phase 3 of the CATIE schizophrenia trial.Extrapyramidal side-effects of antipsychotics in a randomised trial.Application of a single-objective, hybrid genetic algorithm approach to pharmacokinetic model buildingExperimental design and primary data analysis methods for comparing adaptive interventions.Drug and alcohol trajectories among adults with schizophrenia: data from the CATIE study.Tardive dyskinesia in relation to estimated dopamine D2 receptor occupancy in patients with schizophrenia: analysis of the CATIE data.Comparative efficacy between clozapine and other atypical antipsychotics on depressive symptoms in patients with schizophrenia: analysis of the CATIE phase 2E data.Reduction in psychotic symptoms as a predictor of patient satisfaction with antipsychotic medication in schizophrenia: data from a randomized double-blind trial.Change in metabolic syndrome parameters with antipsychotic treatment in the CATIE Schizophrenia Trial: prospective data from phase 1Multi-Objective Markov Decision Processes for Data-Driven Decision SupportCardiovascular risks of atypical antipsychotic drug treatment.Ethnic stratification of the association of RGS4 variants with antipsychotic treatment response in schizophrenia.Association of RGS2 and RGS5 variants with schizophrenia symptom severity.Spiritual struggle and affective symptoms among geriatric mood disordered patientsGenetic predictors of risk and resilience in psychiatric disorders: a cross-disorder genome-wide association study of functional impairment in major depressive disorder, bipolar disorder, and schizophrenia.The cross-sectional GRAS sample: a comprehensive phenotypical data collection of schizophrenic patients.Haplotype-based pharmacogenetic analysis for longitudinal quantitative traits in the presence of dropout.Neurocognitive functioning of individuals with schizophrenia: using and not using drugs.
P2860
Q24187359-00763B8F-42E5-4274-BD36-085BE8AECB41Q24203649-DA3D605F-1BFD-4436-9FBD-530C46215815Q24234961-CADCDB6C-9593-4708-9BD0-20024E59888FQ24236404-18838019-95D0-4E86-92FA-44000F08875CQ24236422-DD075BF4-2EA7-4930-8357-19670C7F1FCDQ24240931-5758AF80-8775-4EAB-A01B-98E3E176565EQ24244248-FEB86EE1-AFCA-4AB9-8443-21298F037590Q24244994-9196A72B-2DEA-49C1-BB25-6F685D2C35F2Q24246232-7EC5A7AC-995D-4D88-96ED-1FF2331A5383Q24246298-0A2E0F37-0668-469D-82EB-27EB6BF29221Q24247235-E3D05187-7294-445B-B4A3-ED319BF2D1ACQ24619631-55528F39-DE40-4E62-BAFD-B6FCD20DFC4EQ24630309-F7AA4AD5-8211-4502-A49F-77B56ECEC5F0Q24650594-9BBA7831-BCA7-4B92-8CFE-A7B04FA2450DQ24802626-01601C94-0DF3-4549-80EF-B043A2329889Q28486019-91F1DD6C-E85D-4818-AE4F-A9A2DDCAA41DQ28659652-8FF8BC4E-8DD8-4F8D-B6D1-45C59DD6B821Q28943274-BF8217A7-861B-41EF-A57F-40511381B307Q30380523-BC93FE40-DDC3-4E7D-AC5C-B5975E0E29E2Q30408983-E868EB16-5780-4975-9ECE-AD960467A101Q30424511-E92F4517-A010-4F2A-9566-C7D46E81B5F1Q30436445-7FDAA297-02F6-4FDF-A99A-7212D28B19A8Q30487308-21DA6A14-3CFA-4A62-A8C6-B9B6EBE11618Q30492645-24D1ED9D-AABA-45F4-9A1A-6626DDA5E97BQ30521370-AE0AF80C-9A8A-4144-9A51-762AF4D5F21AQ30571530-BCA0386C-289D-498A-B88A-D6D2778D744BQ30637935-13E41A65-AFA0-4440-BE65-91939102CBC7Q30747608-DE507DC0-A04E-4D45-B996-A97B5257BD38Q30882594-3C122307-7D4C-4FDB-AED9-E7F7597A407EQ31068505-5E9E033F-4E96-4CD4-B1DD-43CC6C2288A3Q31145823-CF5848FF-313E-40E6-839F-684C12412D34Q31151283-02AD3344-2711-4B96-800F-38613B5DEFDCQ33287409-0251B081-C725-4CDD-A006-8CE503D5AEF6Q33288672-85C93F49-201F-4B34-BCFD-C734A7AAF1D2Q33319041-F72BC642-A0CF-49CF-A9FA-3D13F646928CQ33579025-B6CE023C-5322-4822-83CE-67D608A4662AQ33603700-541949F3-8A72-4AE1-B28B-3896AA97A1CAQ33743615-5AAF8A0F-C839-40FE-AF26-EF2994585A0FQ33754780-0770EF13-0DBC-4816-AAFA-D32D3593E474Q33762494-B0C0C54C-AB96-4DAD-A61C-B18067FED64A
P2860
The National Institute of Mental Health Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) project: schizophrenia trial design and protocol development.
description
2003 nî lūn-bûn
@nan
2003年の論文
@ja
2003年学术文章
@wuu
2003年学术文章
@zh
2003年学术文章
@zh-cn
2003年学术文章
@zh-hans
2003年学术文章
@zh-my
2003年学术文章
@zh-sg
2003年學術文章
@yue
2003年學術文章
@zh-hant
name
The National Institute of Ment ...... sign and protocol development.
@en
The National Institute of Ment ...... of Intervention Effectiveness
@nl
type
label
The National Institute of Ment ...... sign and protocol development.
@en
The National Institute of Ment ...... of Intervention Effectiveness
@nl
prefLabel
The National Institute of Ment ...... sign and protocol development.
@en
The National Institute of Ment ...... of Intervention Effectiveness
@nl
P2093
P1476
The National Institute of Ment ...... sign and protocol development.
@en
P2093
George M Simpson
Ira D Glick
Jeffrey A Lieberman
Jose M Canive
Joseph P McEvoy
Mark F McGee
Marvin S Swartz
Matthew J Byerly
Michael C Stevens
T Scott Stroup
P356
10.1093/OXFORDJOURNALS.SCHBUL.A006986
P407
P577
2003-01-01T00:00:00Z